CVAC: CureVac N.V. Company Short-Term Debt

Symbol and logo of brand CureVac Pharma (CVAC)

This chart illustrates that the market value of CureVac N.V. (CVAC) stands at 0.01, highlighting a crisis of confidence following the failure of its coronavirus drug. The company is currently rebuilding its image by implementing an improved genetic code for stable vaccine storage. The business relies on its alliance with GSK in the field of influenza vaccinations and is scaling costly research and development for cancer treatments.

CVAC (CureVac NV) Company Short-Term Debts history from 07/04/2022 to 01/17/2026

CureVac Pharma - analytical breakdowns and key metrics (CVAC)

- current quotes and average value forecast:
Price Chart CureVac|CVAC - Fair Value Consensus
- market capitalization information:
Market Value CureVac N.V.|CVAC - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share CureVac|CVAC - Book Capitalization|Market Cap to Net Assets Ratio curevac.com|CVAC - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Equity Ratio CureVac N.V.|CVAC - Long-Term Debt to Equity|Short-Term Debt to Capital CureVac N.V.|CVAC - Company Total Debt Obligations|Debt to Book Capitalization Ratio CureVac N.V.|CVAC - Company Long-Term Loans and Borrowings|Company Current Liabilities CureVac|Quick Liquidity curevac.com
- net income and valuation multiples indicators:
CVAC - Net Financial Result
Fundamental company analysis:CVAC - CureVac
Flagship merchandise of CureVac Pharma

For CureVac N.V. (CVAC), which possesses unique stable matrix RNA technology, short-term debt determines current liquidity and financial flexibility. This metric aggregates all obligations with a maturity of up to one year. Analyzing the history of short-term debt allows for an assessment of the company's ability to service loans without emergency equity issuance. A low debt load is critical for maintaining pricing power during the commercialization of vaccines. This confirms the high financial stability of the business.

Competing companies

GILD - Company Short-Term Debt|Company Short-Term Loans and Borrowings CDTX (cidara.com)|Novavax Corp (NVAX) - Company Short-Term Debt|Company Current Liabilities Valneva Vaccines|VIR (Vir Biotechnology, Inc.) - Company Short-Term Debts|Company Short-Term Debts siga.com|Company Current Liabilities EBS (Emergent BioSolutions Inc.)|AVIR (Atea Pharma) - Company Short-Term Loans and Borrowings|Invivyd - Company Current Liabilities|Enanta Pharmaceuticals, Inc - Company Short-Term Debt|Inovio Pharmaceuticals - Company Short-Term Debts|Short-Term Debt Volume hillevax.com HLVX|Kalaris Therapeutics (KLRS) - Company Short-Term Debt|Dyadic International, Inc. - Company Short-Term Loans and Borrowings|Company Current Liabilities NNVC|Company Short-Term Debts Talphera Corporation|Company Short-Term Debt Cocrystal Pharma, Inc. (COCP)|Short-Term Debt Volume trawspharma.com|Company Short-Term Debts DWTX (Dogwood Therapeutics)|QLGN - Company Current Liabilities|ALVR: Company Current Liabilities|VBIV - Company Short-Term Debts|virios.com (VIRI) - Company Short-Term Debt|Vaxart - Company Short-Term Loans and Borrowings